Citizens JMP Sticks to Their Buy Rating for Dynavax (DVAX)
In a report released today, Roy Buchanan from Citizens JMP reiterated a Buy rating on Dynavax, with a price target of $32.00. The company’s shares closed yesterday at $10.95.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Buchanan is an analyst with an average return of -19.8% and a 32.10% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Dynavax, and Enanta Pharmaceuticals.
In addition to Citizens JMP, Dynavax also received a Buy from William Blair’s Matt Phipps in a report issued yesterday. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Dynavax (NASDAQ: DVAX).
Based on Dynavax’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $95.44 million and a net profit of $18.72 million. In comparison, last year the company earned a revenue of $73.8 million and had a net profit of $11.39 million
Read More on DVAX:
Disclaimer & DisclosureReport an Issue
- Buy Rating for Dynavax Driven by Promising Z-1018 Vaccine Developments and Heplisav Revenue Growth
- Dynavax Announces Positive Results for Shingles Vaccine
- Dynavax’s Z-1018 shingles vaccine shows efficacy in Phase 1/2 trial
- Dynavax Technologies Reports Strong Q2 Earnings
- Dynavax price target raised to $32 from $31 at Citizens JMP
